Form 4: Incyte EVP Sells Shares Under 10b5-1 Plan

Incyte's EVP and Chief Medical Officer, Steven H. Stein, sold 15,634 shares of common stock for $101.7 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Steven H. Stein, Executive Vice President and Chief Medical Officer of Incyte Corp., reported a transaction on January 5, 2026.
• The transaction involved the sale of 15,634 shares of Incyte common stock.
• The shares were sold at a price of $101.7 per share.
• This transaction was executed pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities.
• Following the reported transaction, Steven H. Stein beneficially owns 34,203 shares of common stock.
• The remaining beneficial ownership includes an aggregate of 34,203 shares issuable pursuant to previously reported restricted stock units and earned performance shares that have not yet vested.

Sentiment

Score: 4

Explanation: The sale of shares by a key executive, even under a pre-arranged 10b5-1 plan, can be perceived as a slight negative signal by the market, though the plan itself mitigates immediate concerns about insider sentiment.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating a pre-scheduled sale for personal financial planning rather than a reaction to recent company performance or news.

Negatives

• An Executive Vice President and Chief Medical Officer sold 15,634 shares of common stock, which can sometimes be perceived as a negative signal by investors, despite the 10b5-1 plan.

Risks

• Potential for negative investor sentiment or misinterpretation of the insider sale, even though it was pre-planned under a 10b5-1 agreement.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, potentially impacting short-term sentiment, although the 10b5-1 plan context suggests a planned financial move rather than a reaction to new information.

Key Dates

Recommendation

The transaction is a pre-scheduled sale under a Rule 10b5-1 plan, which suggests it is for personal financial planning rather than a reaction to new material non-public information. While insider selling can sometimes be a negative signal, the planned nature of this transaction mitigates immediate concerns, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Incyte, INCY, Form 4, insider trading, stock sale, Steven H. Stein, 10b5-1 plan, executive compensation